Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arda Durmaz

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|June 13, 2025
Anti-thymocyte globulin in immune-mediated cytopenias: A monocentric experience and literature reviewLuca Guarnera, Arooj Ahmed, Carlos Bravo-Perez, et al.
Leukemia|April 29, 2024
Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disordersHussein Awada, Carmelo Gurnari, Valeria Visconte, et al.
Scientific Reports|January 29, 2021
Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastasesAndrew M Baschnagel, Saakshi Kaushik, Arda Durmaz, et al.
Leukemia|February 19, 2021
Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutationsHassan Awada, Cassandra M Kerr, Arda Durmaz, et al.
Leukemia|November 21, 2024
Clonal hematopoiesis in large granular lymphocytic leukemiaNaomi Kawashima, Carmelo Gurnari, Carlos Bravo-Perez, et al.
Leukemia|August 26, 2023
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targetsMinako Mori, Yasuo Kubota, Arda Durmaz, et al.
Nature Communications|May 16, 2020
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressuresRobert Vander Velde, Nara Yoon, Viktoriya Marusyk, et al.
Research Square|March 22, 2023
Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid NeoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Blood Advances|June 16, 2023
Applicability of 2022 classifications of acute myeloid leukemia in the real-world settingEnrico Attardi, Arianna Savi, Beatrice Borsellino, et al.
Journal of Hematology & Oncology|August 3, 2023
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|June 13, 2025
Anti-thymocyte globulin in immune-mediated cytopenias: A monocentric experience and literature reviewLuca Guarnera, Arooj Ahmed, Carlos Bravo-Perez, et al.
Leukemia|April 29, 2024
Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disordersHussein Awada, Carmelo Gurnari, Valeria Visconte, et al.
Scientific Reports|January 29, 2021
Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastasesAndrew M Baschnagel, Saakshi Kaushik, Arda Durmaz, et al.
Leukemia|February 19, 2021
Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutationsHassan Awada, Cassandra M Kerr, Arda Durmaz, et al.
Leukemia|November 21, 2024
Clonal hematopoiesis in large granular lymphocytic leukemiaNaomi Kawashima, Carmelo Gurnari, Carlos Bravo-Perez, et al.
Leukemia|August 26, 2023
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targetsMinako Mori, Yasuo Kubota, Arda Durmaz, et al.
Nature Communications|May 16, 2020
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressuresRobert Vander Velde, Nara Yoon, Viktoriya Marusyk, et al.
Research Square|March 22, 2023
Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid NeoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Blood Advances|June 16, 2023
Applicability of 2022 classifications of acute myeloid leukemia in the real-world settingEnrico Attardi, Arianna Savi, Beatrice Borsellino, et al.
Journal of Hematology & Oncology|August 3, 2023
Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasiaWaled Bahaj, Tariq Kewan, Carmelo Gurnari, et al.
Pageof 6